All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Live Symposium

How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma

At the ESH 7th Translational Research Conference:

Multiple Myeloma

with Martin Kaiser, Mohamad Mohty, and Rakesh Popat

Saturday, October 5, 2024 | 09:10-10:10 CEST

Register now

This independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-08-06T09:40:06.000Z

BCMA-directed immunotherapies in MM: The importance of sequencing


After reading, you'll be able to:
  • After reading this article, learners will be able to cite the resistance mechanisms and sequencing strategies for BCMA-directed therapies in MM.
Share:
 0 minute

Bookmark this article

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

B-cell maturation antigen (BCMA)-targeted therapies have demonstrated promising efficacy in the treatment of relapsed/refractory multiple myeloma (MM).1 However, the sequencing of these therapies remains controversial, with debate centered around the optimal order of administration to maximize patient outcomes while considering factors like resistance mechanisms, toxicities, and treatment accessibility.2

BCMA-directed immunotherapies

BCMA is a cell surface antigen that is heavily involved in the survival and proliferation of plasma cells by interacting with its ligands, B-cell activating factor (BAFF), and A proliferation-inducing ligand (APRIL).1 BCMA is an optimal target for the treatment of MM due to its high expression on malignant cells and relatively low expression on other tissues, therefore minimizing off-target effects of treatment.1

There are a number of T-cell-engaging (TCE) therapies that target BCMA for the treatment of MM. These include antibody-drug conjugates, as well as modern therapies including chimeric antigen receptor (CAR) T cells and bispecific antibodies (bsAbs) (Figure 1).3

Figure 1. Mechanism of action for T-cell engagers* 

Created with BioRender.com.
Ab, antibody; BCMA, B-cell maturation antigen; BM, bone marrow; CAR, chimeric antigen receptor; FcRH5, Fc receptor-homolog 5; GC, germinal center; GPRC5D, G-protein–coupled receptor class C group 5 member D; IFN, interferon; IL, interleukin; MM, multiple myeloma; NK, natural killer; PC, plasma cell; RR, relapsed/refractory; scFv, single-chain fragment variable; SLAM, signaling lymphocytic activation molecule; TNF, tumor necrosis factor.
*Adapted from Cho, et al.3 under the Creative Commons Attribution 4.0 International License.

 BCMA is a member of the tumor necrosis factor receptor (TNFR) superfamily and primarily binds to BAFF and APRIL. In MM, bone marrow stromal cells (BMSCs) are a primary source of BAFF and APRIL.4 These cells create a supportive microenvironment for myeloma cells within the bone marrow. In addition, macrophages and osteoclasts within the bone marrow microenvironment also play significant roles in the secretion of BAFF and APRIL, contributing to the survival, proliferation, and resistance of myeloma cells. Myeloma cells themselves can also secrete BAFF and APRIL, creating an autocrine loop that further supports their own growth and survival.4

The binding of these ligands to BCMA triggers a series of intracellular signaling cascades.4 The activation of these pathways by BCMA supports the proliferation of plasma cells by promoting gene expression that prevents apoptosis and enhances cell division of malignant cells. The disruption of BCMA signaling aims to induce apoptosis and inhibit the proliferation of myeloma cells (Figure 2).4

Figure 2. BCMA signaling pathway*

APRIL, A proliferation-inducing ligand; BAFF, B-cell activating factor; BCMA, B-cell maturation antigen; BM, bone marrow; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TACI, transmembrane activator and CAML interactor.
Created with BioRender.com.
*Adapted from Yu, et al.4 under the Creative Commons Attribution 4.0 International License.

 There are a number of approved TCEs for the treatment of MM (Table 1). Bispecific antibody and CAR T-cell therapies were initially investigated in the relapsed/refractory (RRMM) setting, primarily in the heavily pretreated population. However, TCEs are increasingly being investigated in earlier lines of therapy, including in the first line.5,6

Table 1. Currently approved BCMA-directed TCEs in RRMM*

Agent

Category

FDA approval Date

FDA indication

EU approval date

EU indication

Idecabtagene vicleucel

CAR T-cell therapy

March 20217

After ≥4 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb7

August 20218

After ≥3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb, with progression after the last therapy8

Ciltacabtagene autoleucel

CAR T-cell therapy

February 20229

After ≥4 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb9

May 202210

After ≥3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb, with progression after the last therapy10

Teclistamab

Bispecific antibody

October 202211

After ≥4 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb11

August 202212

After ≥3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb, with progression after the last therapy12

Elranatamab

Bispecific antibody

August 202313

After ≥4 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb13

December 202314

After ≥3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 mAb, with progression after the last therapy14

CAR, chimeric antigen receptor; IMiD, immunomodulatory agent; mAb, monoclonal antibody; PI, proteosome inhibitor; RRMM, relapsed/refractory multiple myeloma; TCE, T-cell engager.

 Resistance to BCMA-directed therapies15

Although BCMA is considered an optimal target for therapy, resistance is common and can arise through several mechanisms. The primary mechanism of resistance to BCMA is as a result of the downregulation or loss of BCMA expression on the surface of myeloma cells. Genetic mutation or deletions in the TNFRSF17 gene, which encodes BCMA, can reduce antigen expression, making BCMA-directed therapies less effective.15 Antigen escape is a notable mechanism of resistance where malignant cells downregulate antigen expression under therapeutic pressure. This can occur through selective pressure favoring clonal evolution and expansion of BCMA-negative or low-expressing cells15 (Figure 3). T-cell exhaustion further contributes to resistance to BCMA-directed therapies. The persistent stimulation of T cells by tumor antigens, paired with the immunosuppressive environment within the bone marrow leads to T-cell exhaustion and reduced efficacy of BCMA-directed therapies (Figure 3).16

Figure 3. Impact of T-cell exhaustion and BCMA loss on CAR T-cell action* 

CAR, chimeric antigen receptor; MM, multiple myeloma.
*Adapted from Lee, et al.
15 and D’Agostino and Raje.16

 The need for novel approaches in RRMM

Despite continual advances in the treatment of MM, many patients still go on to experience disease progression and relapse, highlighting an unmet need for more durable and effective treatment approaches in this setting.17 There is increasing heterogeneity amongst patients with RRMM due to complex treatment histories and resistance to therapies. The prognosis for patients with RRMM is often poor, with patients commonly experiencing diminished duration of response and higher rates of toxicity with increasing lines of therapy.17 The importance of sequencing therapies, and the development of individualized treatment plans is vital to reduce resistance and achieve an optimal response in the absence of intolerable adverse events.

Sequencing strategies

There are a number of factors which influence the optimal sequencing of BCMA-directed therapies, including:

  • The stage of disease and patient factors18:
    • Comorbidities and overall health status play a key role in developing individual strategies. Patients with a significant number of comorbidities, or those who are frail, may benefit more from less-aggressive therapies to reduce the risk of developing intolerable toxicities.
    • Younger and fitter patients may benefit from early intervention with therapies that have the highest efficacy rates such as CAR T-cell therapy and bispecific antibodies. Logically, the most effective and toxic therapies being delivered in earlier lines is rational to elicit the best response when the patient is more able and potentially willing to tolerate them.
  • Prior treatments19:
    • Prior treatment history, including responses and acquired toxicities, are important to guide further management strategies. For example, in certain situations, patients who have been previously treated with a BCMA-directed therapy may benefit more from treatments which target an alternative antigen. However, there have also been favorable responses noted when anti-BCMA T-cell engagers are administered after an anti-BCMA CAR T-cell therapy.
    • Furthermore, in patients who relapse quickly after directed immunotherapies, there should be a consideration for the possible mechanisms of resistance and potential selection of an alternative target.
    • Patients who have relapsed a long time after treatment with a BCMA-directed therapy may still be considered for future BCMA-directed treatment, potentially with an alternative therapy in the interim.
  • Availability and access20:
    • There should be practical considerations made for the accessibility of certain therapies, such as CAR T-cell therapy, where availability is particularly limited and there are longer manufacturing times.
      • However, future directions with CAR T-cell therapies include investigation into academic CAR T with notably shorter manufacturing times.21
      • Furthermore, the outpatient administration of ciltacabtagene autoleucel (cilta-cel) is being explored in the CARTITUDE-2 and CARTITUDE-5 studies, which have the potential to increase accessibility to treatment, particularly in those who live significant distances from infusion centers.22,23
    • In patients with particularly aggressive disease, it may be more appropriate to select a bispecific antibody that is available off-the-shelf to reduce the risk of mortality during manufacturing time.23
    • Certain novel therapies, such as CAR T cells, are not approved globally, with some areas in South America having no approved MM-specific CAR T-cell therapies at all.23

Clinical trial data to support sequencing strategies in MM

There are a number of clinical trials that have evaluated the effect of sequencing in therapies for RRMM. A significant difference in outcomes based on prior therapies has been observed with BCMA-directed therapies, further emphasizing the need for individualized treatment strategies with consideration for prior therapy.6

As part of the MajesTEC-1 (NCT03145181) clinical trial, patients with prior treatment with BCMA-directed therapies in Cohort C were observed for the influence the type of prior therapy had on response to teclistamab, a BCMA-directed bispecific antibody (Figure 4).24 Ultimately, data determined little difference based on the type of therapy administered.

Similarly, in a study of teclistamab in the real-world setting, there was a significant difference in response to therapy based on the nature of the prior therapy received. Patients who had received prior treatment with an antibody-drug conjugate and a CAR T-cell therapy had a higher overall response rate compared with either type of drug alone (Figure 5).25

A difference in progression-free survival (PFS) was observed in Cohort C of the CARTITUDE-2 (NCT04133636) trial of cilta-cel based on prior therapy. CAR T-cell therapy after prior anti-BCMA bispecific antibodies was associated with significantly lower PFS than anti-BCMA-naïve patients at 2.7 months and 8.9 months. This may suggest that CAR T-cell therapies be prioritized over anti-BCMA bispecific antibody, where feasible.26,27

BCMA-directed therapies in earlier lines of treatment

The implementation of BCMA-directed therapies into earlier lines of therapy is a current point of discussion for the management of MM. The key rationale for investigation into earlier lines are centered around overcoming the mechanisms of resistance, particularly to CAR T cells. This could be achieved due to:

  • Presence of fitter T cells in earlier disease
    • Having treatment with few prior lines of therapy is associated with improved persistence of CAR T cells, and ultimately increased rates of myeloma cell death
  • Increased immunogenicity of tumor cells
    • Less pre-treatment heterogeneity in the antigen density expressed on tumor cells results in reduced resistant clone selection
  • Lower tumor burden
    • Implementation of CAR T cells in earlier lines means tumor cells possess a lower proliferative potential

Additionally, there tends to be lower attrition rates for therapies in later lines; therefore, it may be justified to implement treatments with the highest response rates as early as possible in the treatment paradigm. For example, in Austria, 85% of patients with MM were unable to receive treatment beyond the third line of therapy, with similar data observed in the US, France, and Australia, highlighting the need for effective therapies in early lines where attrition rates remain high.23

Trials investigating BCMA-directed therapies in earlier lines of therapy are outlined in Table 2.

Table 2. Summary of trials investigating BCMA-directed therapies in earlier lines of therapy

Agent

Trial

Phase

Intervention

Cilta-cel

CARTITUDE-4 (NCT04181827)

Phase III

Cilta-cel for the treatment of patients with lenalidomide-refractory MM after 1–3 prior lines of therapy28

Cilta-cel

CARTITUDE-5 (NCT04923893)

Phase III

Bortezomib-lenalidomide-dexamethasone, followed by cilta-cel for the treatment of newly diagnosed MM where transplant is not planned as initial therapy29

Cilta-cel

CARTITUDE-6 (NCT05257083)

Phase III

Daratumumab-bortezomib-lenalidomide-dexamethasone followed by cilta-cel for the treatment of newly diagnosed MM29

Ide-cel

KarMMa-7 (NCT04855136)

Phase I/II

Ide-cel in combination with other therapies for the treatment of RRMM with either 1–3 or ≥3 prior regimens30

Ide-cel

KarMMa-9 (NCT06045806)

Phase III

Ide-cel with lenalidomide maintenance for the treatment of newly diagnosed multiple myeloma with suboptimal response after auto-SCT.31

Teclistamab

MajesTEC-7 (NCT05552222)

Phase III

Teclistamab-daratumumab-lenalidomide for the treatment of newly diagnosed multiple myeloma, either ineligible for or not intended for auto-HSCT.32

Elranatamab

MagnetisMM-7 (NCT05317416)

Phase III

Elranatamab post-transplant for the treatment of newly diagnosed multiple myeloma.33

Auto-HSCT, autologous hematopoietic stem cell transplant; MM, multiple myeloma; RRMM, relapsed/refractory multiple myeloma.

 Future directions

The strategic sequencing of BCMA-directed immunotherapies is vital to improve outcomes in patients with RRMM. Considering the unique mechanisms of action, efficacy, and toxicity profiles of BCMA-directed therapies, as well as patient factors and prior therapies, there is a need to tailor treatment plans to the individual needs of patients. Ongoing research into the optimal sequence and combination strategies for BCMA- and other directed immunotherapies in MM are crucial to maximize the efficacy of treatments, and at the same time limit the associated toxicities.

This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

As a result of this content, I commit to reviewing the latest clinical data to help inform sequencing treatment in my clinical practice.
6 votes - 30 days left

  1. Sammartano V, Franceschini M, Fredducci S, et al. Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resist. 2023;6(1):169-181. DOI: 10.20517/cdr.2022.138 

  2. Walia A, Haslam A, Tuia J, et al. Multiple myeloma: challenges with deciding the optimal sequencing strategy. Front Pharmacol. 2023;14:1231720. DOI: 10.3389/fphar.2023.1231720
  3. Cho SF, Yeh TJ, Anderson KC, et al. Bispecific antibodies in multiple myeloma treatment: A journey in progress. Front Oncol. 2022;12:1032775. DOI: 10.3389/fonc.2022.1032775
  4. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125. DOI: 10.1186/s13045-020-00962-7
  5. U.S. Food and Drug Administration. Development & Approval Process | Drugs. https://www.fda.gov/drugs/development-approval-process-drugs. Published August 8, 2022. Accessed July 22, 2024. 
  6. Harousseau JL, Mohty M. Sequencing anti-BCMA therapies in myeloma. Blood. 2023;141(3):211-212. DOI: 10.1182/blood.2022018157
  7. U.S. Food and Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-idecabtagene-vicleucel-multiple-myeloma. Published March 29, 2021. Accessed July 26, 2024. 
  8. Bristol Myers Squibb. Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma. https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Abecma-Idecabtagene-Vicleucel-the-First-Anti-BCMA-CAR-T-Cell-Therapy-for-Relapsed-and-Refractory-Multiple-Myeloma/default.aspx. Published August 19, 2021. Accessed July 26, 2024. 
  9. U.S. Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Published July 3, 2022. Accessed July 26, 2024. 
  10. Johnson & Johnson. European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. https://www.jnj.com/media-center/press-releases/european-commission-grants-conditional-approval-of-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma. Published May 26, 2022. Accessed July 26, 2024. 
  11. U.S. Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Published October 25, 2022. Accessed July 26, 2024. 
  12. Johnson & Johnson. Janssen Marks First Approval Worldwide for TECVAYLI® (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma. https://www.jnj.com/media-center/press-releases/janssen-marks-first-approval-worldwide-for-tecvayli-teclistamab-with-ec-authorisation-of-first-in-class-bispecific-antibody-for-the-treatment-of-patients-with-multiple-myeloma. Published August 24, 2022. Accessed July 26, 2024. 
  13. U.S. Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma. Published August 14, 2023. Accessed July 26, 2024. 
  14. Pfizer. European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma. https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-elrexfior-relapsed-and. Published December 8, 2023. Accessed July 26, 2024. 
  15. Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024;143(13):1211-1217. DOI: 10.1182/blood.2023022499
  16. D’Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2020;34(1):21-34. DOI: 10.1038/s41375-019-0669-4
  17. Bazarbachi AH, Al Hamed R, Malard F, Harousseau JL, Mohty M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343-2357. DOI: 10.1038/s41375-019-0561-2
  18. Davis JA, Dima D, Ahmed N, et al. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. Transplant Cell Ther. 2024;30(3):298-305. DOI: 10.1016/j.jtct.2023.12.015

  19. Mishra AK, Gupta A, Dagar G, et al. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines (Basel). 2023;11(11):1721. DOI: 10.3390/vaccines11111721
  20. Mikhael J, Fowler J, Shah N. Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access. JCO Oncol Pract. 2022;18(12):800-807. DOI: 10.1200/OP.22.00315
  21. Delgado J, Juan M, Calvo G, et al. The development of academic CAR T cells. Lancet Haematol. 2024;11(7):e484-e485. DOI: 10.1016/S2352-3026(24)00170-4
  22. Gajra A, Zalenski A, Sannareddy A, Jeune-Smith Y, Kapinos K, Kansagra A. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. Pharmaceut Med. 2022;36(3):163-171. DOI: 10.1007/s40290-022-00428-w
  23. Einsele H. Moving CAR-T into first-line therapy in Multiple Myeloma. Presented at: 6th European CAR T-cell Meeting; February 15–17, 2024; Valencia, ES.
  24. Raje N. Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma. Presented at: 64th ASH Annual Meeting and Exposition; December 10–13, 2022; New Orleans, US.
  25. Dima D. Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma. Presented at: 65th ASH Annual Meeting and Exposition; December 9–12, 2023; San Diego, US.
  26. Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141(3):219-230. DOI: 10.1182/blood.2022015526
  27. Razzo B, Garfall AL, Cohen AD. Options at the time of relapse after anti-BCMA therapy. Hematology. 2023;2023(1):450-458. DOI: 10.1182/hematology.2023000445
  28. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335-347. DOI: 10.1056/NEJMoa2303379
  29. Jurgens E, Usmani SZ. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM. Clin Lymphoma Myeloma Leuk. 2024;24(5):277-284. DOI: 10.1016/j.clml.2024.01.001
  30. Raje NS, Berdeja JG, Rodriguez-Otero P, et al. KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2021;138(Supplement 1):4830-4830. DOI: 10.1182/blood-2021-147412
  31. Mateos MV, Cohen AD, Harrison, Simon J. Efficacy and safety of idecabtagene vicleucel (idecel) with lenalidomide (len) maintenance versus len maintenance alone in adult patients (pts) with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplantation (ASCT): Phase 3 KARMMA-9 trial. Haematologica. 2024;109:25‐26.

  32. Krishnan AY, Manier S, Terpos E, et al. MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant. Blood. 2022;140(Supplement 1):10148-10149. DOI: 10.1182/blood-2022-160173
  33. Mateos Manteca MV, Grosicki S, Kim K, et al. MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. JCO. 2023;41(16_suppl):TPS8066-TPS8066. DOI: 10.1200/JCO.2023.41.16_suppl.TPS8066